“Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 2, Mar. 2022, p. s1, https://doi.org/10.25251/skin.6.supp.1.